Medication info
Istar Plus Tablet 80/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)

Istar Plus Tablet 80/5/10 mg (Telmisartan, Amlodipine, Rosuvastatin)

Prescription medicationTabletOral
Ingredient · strength
Telmisartan›80mg / 1 tabletAmlodipine Besylate›6.935mg / 1 tabletRosuvastatin Calcium›10.4mg / 1 tablet
Manufacturer / importer
Introbiopharma Co., Ltd.
Appearance
Bright pink oval film-coated tablet
Packaging
30 tablets per bottle
Approval status
Active

MFDS item code 202402951 · Approved 2024.12.12

Summary

Main use
Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk
Who takes it
Adults
Adult dose
Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may switch to this drug (a combination product with the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this drug 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this drug 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, treatment should be initiated at a low dose and the dose increased gradually because amlodipine clearance is reduced. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue this diet throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this drug, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, the potential risk due to the increase in rosuvastatin Cmax should be assessed and patients should be monitored closely when administering this drug.

Ingredients

Manufacturer
Introbiopharma Co., Ltd.

Efficacy & effects

Treatment of hypertension, improvement of dyslipidemia, and inhibition of atherosclerosis progression and cardiovascular disease risk

  • Essential hypertension
  • primary hypercholesterolemia
  • heterozygous familial hypercholesterolemia
  • mixed hyperlipidemia
  • homozygous familial hypercholesterolemia
  • hypercholesterolemia
  • primary dysbetalipoproteinemia
  • increased high-sensitivity C-reactive protein
  • hypertension
  • low HDL cholesterol levels
  • smoking
  • family history of early coronary artery disease
View approved original text

This medication is suitable for patients with essential hypertension who have difficulty controlling their blood pressure even with the combination of telmisartan and amlodipine, as well as patients with hyperlipidemia-related conditions. The telmisartan/amlodipine combination helps stabilize blood pressure and effectively lowers blood cholesterol levels in cases such as primary hypercholesterolemia and mixed hyperlipidemia. Additionally, it is used as an adjunct to the diet in patients with homozygous familial hypercholesterolemia or dysbetalipoproteinemia, which can delay the progression of atherosclerosis. This medication reduces the risk of cardiovascular events in patients with hypercholesterolemia, particularly helping to reduce the risk of stroke, myocardial infarction, and complications following vascular interventions. Therefore, this medication is effectively used for the management of hypertension and hyperlipidemia and for the prevention of cardiovascular diseases.

How to take

Adult dose

Take 1 tablet once daily with water, regardless of meals. If possible, it is recommended to take it at the same time each day (e.g., in the morning). This drug is for use in adults only. The dose should be individualized for each patient based on the efficacy and tolerability of the telmisartan/amlodipine combination and rosuvastatin. For patients taking a telmisartan/amlodipine combination and rosuvastatin as separate products, they may switch to this drug (a combination product with the same amounts of each active ingredient) for convenience. ○ Telmisartan/amlodipine combination Before administering the telmisartan/amlodipine combination, it is recommended that the dose of each individual component (amlodipine or telmisartan) be adjusted. However, if blood pressure is not controlled with the individual components, switching directly to the telmisartan/amlodipine combination may be considered as follows. - 40/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or telmisartan 40 mg. - 80/5 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or this drug 40/5 mg. - 40/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg. - 80/10 mg: For patients whose blood pressure is not adequately controlled with amlodipine 10 mg or this drug 40/10 mg. ◦ Patients with renal impairment: No dose adjustment is necessary for patients with mild or moderate renal impairment. For patients with severe renal impairment, however, it is recommended to initiate treatment at a low dose and increase the dose gradually. Periodic monitoring of serum potassium and creatinine levels is also recommended. ◦ Patients with hepatic impairment: The daily dose of telmisartan should not exceed 40 mg in patients with mild or moderate hepatic impairment. ◦ Elderly patients: In patients aged 75 years or older, treatment should be initiated at a low dose and the dose increased gradually because amlodipine clearance is reduced. ○ Rosuvastatin 1. Primary hypercholesterolemia (type IIa, including heterozygous familial hypercholesterolemia), mixed dyslipidemia (type IIb), primary dysbetalipoproteinemia (type III), and homozygous familial hypercholesterolemia Patients should follow a standard cholesterol-lowering diet before and during treatment with rosuvastatin, and continue this diet throughout the treatment period. Rosuvastatin may be taken at any time of day, regardless of meals. The initial dose is 5 mg once daily; if a greater reduction in LDL cholesterol is needed, the dose may be adjusted to the maintenance dose. The maintenance dose is 10 mg once daily, which controls the condition in most patients. The maintenance dose should be appropriately adjusted at intervals of 4 weeks or more according to LDL cholesterol levels, treatment goals, and the patient's response, and may be increased up to a maximum of 20 mg per day. 2. Elderly patients: No dose adjustment is necessary. 3. Patients with renal impairment: No dose adjustment is necessary in patients with mild or moderate renal impairment. Do not administer to patients with severe renal impairment. Particular caution should be exercised when administering rosuvastatin 20mg to patients with moderate renal impairment. 4. Patients with hepatic impairment: No increase in systemic exposure to rosuvastatin was observed in patients with a Child-Pugh score of 7 or less, but exposure increased in patients with a Child-Pugh score of 8 or 9. Renal function testing should be considered in these patients. There is no experience with administration to patients with a Child-Pugh score greater than 9. Do not administer rosuvastatin to patients with active liver disease. 5. Race: Because systemic exposure to rosuvastatin is increased in Asian patients, the recommended initial dose is 5 mg. Administration of the 40 mg dose is contraindicated. 6. Patients predisposed to myopathy: The recommended initial dose for patients predisposed to myopathy is 5 mg. Administration of rosuvastatin 40 mg is contraindicated in some of these patients. In a drug interaction study of the active ingredients of this drug, telmisartan/amlodipine 80/10mg and rosuvastatin 20mg, rosuvastatin Cmax increased approximately 2.4-fold and AUC approximately 1.3-fold in the presence of telmisartan/amlodipine. Therefore, the potential risk due to the increase in rosuvastatin Cmax should be assessed and patients should be monitored closely when administering this drug.

Precautions

This medication can cause serious harm to the fetus and neonate if taken during pregnancy, so it should be discontinued immediately upon confirmation of pregnancy. Do not take this medication if you are allergic to any ingredients it contains or have a history of certain hereditary angioedema. Patients with severe liver disorders or bile excretion issues, as well as patients with severe kidney disorders, should not use this medication. Elderly patients or those with specific kidney and liver conditions should exercise extra caution when using this medication for hypertension or dyslipidemia. Symptoms such as muscle pain or weakness may occur, so if such symptoms arise, consult a doctor immediately. Since this medication has blood pressure-lowering effects, patients with hypotension or unstable blood pressure should be cautious when taking it. There may be interactions when taken with other medications, so inform healthcare providers of any other medications being taken. Nursing mothers are advised not to take this medication, and if it is absolutely necessary, breastfeeding should be discontinued. This medication is not recommended for children under 18 years of age. In case of overdose, symptoms such as blood pressure decrease, dizziness, heart, and kidney problems may appear, so immediate medical attention is needed. It is important to regularly monitor liver function and muscle status with blood tests while taking this medication. Store this medication out of reach of children, and keep it in its original container for safety.

Side effects

Viral upper respiratory tract infection, respiratory distress, anal bleeding, dyspepsia, atopic dermatitis, peripheral edema, chronic gastritis, various gastrointestinal disorders, hiatal hernia, dysuria, rhinitis, discomfort in the oropharynx, lung disease, unspecified gastrointestinal disease, benign gastrointestinal neoplasm, hemorrhoids, skeletal pain, osteoporosis, sensory disturbance, movement disorders, atherosclerosis, frequent urination, tinnitus, hearing loss, bad breath, fatty liver, upper respiratory infection, lower back pain, sinusitis, diarrhea, pharyngitis, erectile dysfunction, increased sweating, flushing, allergy, fever, leg pain, fatigue, palpitations, dependent edema, angina, rapid heartbeat, leg edema, abnormal ECG, insomnia, drowsiness, migraine, sensory abnormality, involuntary muscle contraction, dermatitis, rash, eczema, pruritus, frequent urination, cystitis, angioedema, headache, fatigue, nausea, abdominal pain, drowsiness, arrhythmia, bradycardia, chest pain, peripheral ischemia, syncope, orthostatic hypotension, vasculitis, peripheral neuropathy, tremor, appetite loss, constipation, dysphagia, pancreatitis, vomiting, gingival hyperplasia, asthenia, burning sensation, fatigue, pain, stiffness, weight gain, weight loss, arthralgia, osteoarthritis, muscle cramps, myalgia, sexual dysfunction, insomnia, neurosensitization, depression, abnormal dreams, anxiety, derealization, epistaxis, angioedema, erythema multiforme, rash, erythematous rash, papular rash, diplopia, eye pain, ear pain, urinary dysfunction, nocturia, dry mouth, hyperglycemia, thirst, leukopenia, purpura, thrombocytopenia, myalgia, myopathy, rhabdomyolysis, asthenia, polyneuropathy, amnesia, peripheral neuropathy, cough, jaundice, hepatitis, Stevens-Johnson syndrome, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, lupus-like syndrome, muscle rupture, immune-mediated necrotizing myopathy, hematuria, edema, headache, dizziness, ALT increase, chest pain, cough, CK increase, constipation, AST increase, asthenia, arthralgia, fatigue, numbness, sensory abnormality, chest discomfort, appetite loss, abdominal distension, syncope, generalized pain, muscle cramps, gout

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container that protects it from light, and kept at room temperature between 1°C and 30°C. By doing so, the effectiveness of the medication can be well maintained.

Appearance and packaging

Appearance

Bright pink oval film-coated tablet

Package unit

30 tablets per bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.